Cancer patients get chance to continue promising treatment in Safety-Focused Follow-Up study
Disease control
Not yet recruiting
This study allows cancer patients who benefited from adagrasib treatment in previous trials to continue receiving the medication while researchers monitor long-term safety. The trial focuses on people with advanced solid tumors including lung and colorectal cancers who are alread…
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC